Skip directly to content

World Antibiotic Awareness Week 12–18 November 2018



Pfizer Media Contact:

Shariq Yaqub



Pfizer Aims to Slow Growing Global Public Health Threat of Antimicrobial Resistance

Antimicrobial resistance results in 700,000 annual deaths globally; estimated to reach 10 million by 20501


Pfizer is leveraging its long-standing heritage in infectious diseases to help prevent and combat antimicrobial resistance, one of the biggest threats to global health


Pakistan – 12-18 November, 2018– Pfizer Pakistan in recognition of World Antibiotic Awareness Week (WAAW), 12–18 November 2018, today reaffirms its commitment to working with industry partners and policymakers to help prevent and combat the global public health threat of antimicrobial resistance (AMR). Medical experts, including the World Health Organization (WHO), agree that if no action is taken, AMR is estimated to result in approximately 10 million deaths globally each year by 2050.1


AMR can affect anyone, of any age, in any country. It occurs when pathogens change and find ways to resist the effects of antibiotics. The pathogens survive, grow and spread their resistance.1 This process of adaptation leads to AMR.1 If no solution is found, the consequences of AMR could be devastating. Minor infections and injuries could become life-threating, and serious infections such as pneumonia could become impossible to treat. Further, many routine medical procedures could be too risky to perform because of the risk of becoming infected while in hospital by a multi-drug resistant pathogen.1


SM Wajeeh, Country Manager for Pfizer Pakistan said; “We at Pfizer are fully cognizant of this important issue of AMR and have been working with relevant stakeholders to make our contribution towards managing it. On the occasion of World Antibiotic Awareness Week 2018, we are pleased to partner with MMIDSP, which is leading the way for creating awareness on AMR in Pakistan. Pfizer core values remain focused on our patient’s wellness, and we are working together on projects that positively impact overall health in Pakistan.”


Dr. Aamer Ikram, President of MMIDSP said on this occasion: “MMIDSP takes the pride in launching the initiatives in the country to curb antimicrobial resistance (AMR) through “Antibiotic Stewardship Initiative in Pakistan (ASIP)”. The Society has organized multiple events in collaboration with Pfizer Pakistan for creating awareness and imparting training at both institutional and community levels to address the injudicious overuse of antibiotics with ever increasing AMR. It has reached out to major stakeholders, professional societies and policy makers within and outside the government for collaboration in tackling AMR at national level. Many national and provincial initiatives have been taken across Pakistan. On this World Antibiotic Awareness Week 2018, MMIDSP appeals to all stakeholders that it is our responsibility to join hands in these national efforts to end the menace of AMR.”


As one of the leading global providers of anti-infective medicines, Pfizer is committed to working closely with the infectious disease community to address AMR, through:[1]

Active stewardship to support education efforts for both healthcare professionals and the general public, by offering training and education to raise public awareness of AMR. Pfizer Pakistan conducted the SHAPES Critical Care educational summit to address the Antimicrobial resistant and the stewardship program to highlight the disease burden and critical care patient management.
Innovative surveillance tools such as the Antimicrobial Testing Leadership and Surveillance (ATLAS) database which provides physicians and the global health community with free access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns in more than 70 countries.[2],[3]  In January 2018, the Access to Medicines Benchmark Report on AMR noted that Pfizer’s ATLAS program “stands out among all AMR surveillance programs,” as it is completely accessible to the infectious disease community.”[4]
Global policy leadership to facilitate antibiotic and vaccine development, access and proper use, and partnering with governments and organizations to address AMR.  Pfizer Pakistan partnered with Medical Microbiology and Infectious Disease Society of Pakistan (MMIDSP) and other medical institutions to combat the challenges of AMR Microbial resistant and implementation of AMS. 
Expanding its diverse portfolio of anti-infective medicines and vaccines to help treat and prevent serious infections around the world. Today, Pfizer is one of the leading providers of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 potentially life-saving medicines. This includes 45 antibiotics that are currently included on the WHO’s essential medicines list6 and innovative vaccines that have been proven to help reduce reliance on antibiotics.
Applying responsible manufacturing practices that minimize impact to human health and the environment.


In addition to the efforts being undertaken by the infectious disease community, there are things individuals can do every day to help prevent the development and mitigate the spread of AMR. First, don’t take any medicine, especially antibiotics, unless you need them. For example, antibiotics – which target bacteria – are ineffective in treating the common cold, which is most often caused by a virus. If you are prescribed an antibiotic, make sure to take it exactly as instructed by your doctor. Finish the course of medicine, don’t miss any doses, and don’t take medicines prescribed for someone else. Keeping up to date with your vaccinations also reduces the chance that you’ll catch an infection that needs to be treated with an antimicrobial.


About Antimicrobial Resistance (AMR)

The World Health Organization (WHO) characterizes antimicrobial resistance (AMR) as one of the biggest threats to global public health today; AMR can affect anyone at any age in any country, threatening our ability to treat serious infections and provide standard medical procedures.[5] Gram-negative bacteria, the cause of many healthcare-associated infections (HAIs), have become increasingly resistant to many available antibiotic treatments.[6] These infections are associated with increased patient mortality and cost of care.8  At present, approximately 700,000 deaths per year are attributed to antimicrobial resistance globally, with an increase to 10 million every year predicted by 2050 if no action is taken to address this issue.1


About Pfizer’s Commitment to Antimicrobial Resistance

Pfizer recognizes the serious public health threat associated with AMR and has taken significant steps to address this issue. In early 2016, Pfizer was a signatory of the Declaration on Combating Antimicrobial Resistance (AMR), a global call-to-action drafted and signed by more than 100 companies and 13 trade associations encouraging greater industry and government collaboration to address the issue of antimicrobial resistance.[7] As a follow-up to the AMR Declaration, Pfizer and 12 industry partners unveiled the “Industry Roadmap to Combat Antimicrobial Resistance,” a comprehensive plan of action, that lays out four key commitments we pledge to deliver.[8]


Earlier this year, Pfizer was recognized by the Access to Medicine Foundation’s AMR Benchmark Report6 as among the top performing large research-based pharmaceutical companies in the infectious diseases market, with acknowledgment of strengths in surveillance as demonstrated by the ATLAS database, strong manufacturing commitments and our robust vaccines pipeline.

Pfizer Pakistan: Working together for a healthier world™

Pfizer has been working for the health and wellbeing of patients in Pakistan for more than 50 years. Our business in Pakistan is part of the global Pfizer Inc. operations, first founded in 1849 in New York, USA. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our operations in Pakistan, please visit us at

DISCLOSURE NOTICE: The information contained in this release is as of September, 2018. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information regarding Pfizer’s efforts to address antimicrobial resistance and Pfizer’s anti-infectives and vaccines portfolios, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of Pfizer’s anti-infectives and vaccines portfolios; the uncertainties inherent in research and development, including the ability to meet anticipated clinical trial commencement and completion dates and regulatory submission dates, as well as the possibility of unfavorable clinical trial results, including unfavorable new clinical data and additional analyses of existing data; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications may be filed in any jurisdictions for Pfizer’s investigational anti-infectives and vaccines; whether and when regulatory authorities in any such jurisdictions where applications may be filed or pending may approve such applications, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted and, if approved, whether such products will be commercially successful; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of Pfizer’s anti-infectives and vaccines; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results,” as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and


[1] Pfizer Annual Review 2017. Anti-Infectives. Available at: Last accessed October 2018.

[2] Pfizer. Antimicrobial Testing Leadership and Surveillance.

Available at: Last accessed October 2018.

[3] AMR Industry Alliance. Case study: Pfizer - Antimicrobial Testing Leadership and Surveillance (ATLAS) Available at:

antimicrobial-testing-leadership-and-surveillance-atlas/ Last accessed October 2018.

[4] Access to Medicine Foundation. 2018 Antimicrobial Resistance Benchmark report. January 2018. Available at: Last accessed October 2018.

[5] World Health Organization. Antibiotic Resistance Factsheet. February 2018. Available at: Last accessed October 2018.

[6] Vasoo S, Barreto JN, Tosh PK. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clinic Proc. 2015;90:395-403. 

[7] International Federation of Pharmaceutical Manufacturers & Associations. Industry Roadmap for Progress on Combating Antimicrobial Resistance. September 2016. Available at: Last accessed October 2018.

[8] AMR Industry Alliance. AMR Roadmap Launched. September 2016. Available at: Last accessed October 2018.